Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia

Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells

(2015) Maeva Dufies et al.   Oncotarget

Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma

(2013) I. Ben-Batalla et al.   BLOOD

Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target

(2013) I.-K. Park et al.   BLOOD

Axl/Gas6 pathway positively regulates FLT3 activation in human natural killer cell development

(2013) Il-Kyoo Park et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

GAS6 expression identifies high-risk adult AML patients: potential implications for therapy

(2013) S P Whitman et al.   LEUKEMIA

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

(2013) Muhammed Murtaza et al.   NATURE

First Axl inhibitor enters clinical trials

(2013) Cormac Sheridan   NATURE BIOTECHNOLOGY

Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer

(2013) Manish A. Shah et al.   PLoS One

The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells

(2013) A. S. Meyer et al.   Science Signaling

Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias

(2012) N. A. Zorko et al.   BLOOD

An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

(2012) L. A. Byers et al.   CLINICAL CANCER RESEARCH

Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

(2012) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutations in UVSSA cause UV-sensitive syndrome and destabilize ERCC6 in transcription-coupled DNA repair

(2012) Xue Zhang et al.   NATURE GENETICS

Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA

(2011) Mark Mackiewicz et al.   BREAST CANCER RESEARCH AND TREATMENT

Activation of TYRO3/AXL Tyrosine Kinase Receptors in Thyroid Cancer

(2011) E. Avilla et al.   CANCER RESEARCH

Micro RNAs as a new therapeutic target towards leukaemia signalling

(2011) Megan Y. Murray et al.   CELLULAR SIGNALLING

miR-34a Induces the Downregulation of Both E2F1 and B-Myb Oncogenes in Leukemic Cells

(2011) G. Zauli et al.   CLINICAL CANCER RESEARCH

Axl-dependent signalling: a clinical update

(2011) Vyacheslav A. Korshunov   CLINICAL SCIENCE

Reversible Resistance Induced by FLT3 Inhibition: A Novel Resistance Mechanism in Mutant FLT3-Expressing Cells

(2011) Ellen Weisberg et al.   PLoS One

FLT3 as a therapeutic target in AML: still challenging after all these years

(2010) T. Kindler et al.   BLOOD

AXL Is an Essential Factor and Therapeutic Target for Metastatic Ovarian Cancer

(2010) E. B. Rankin et al.   CANCER RESEARCH

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2

(2010) J. P. Eder et al.   CLINICAL CANCER RESEARCH

Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL

(2009) L. Liu et al.   CANCER RESEARCH

FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML

(2009) Ellen Weisberg et al.   DRUG RESISTANCE UPDATES

The Axl/Gas6 pathway is required for optimal cytokine signaling during human natural killer cell development

(2008) I.-K. Park et al.   BLOOD

Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia

(2008) Chih-Chen Hong et al.   CANCER LETTERS

Simultaneous evaluation of viability and Bcl-2 in small-cell lung cancer

(2008) A. Santos et al.   CYTOMETRY PART A